Search
Displaying 431–440 of 664 for “retinitis clinical trial”
-
Your Dollar Makes a Difference
Foundation NewsAt the Foundation Fighting Blindness, a dollar is more than just a dollar – it’s a path to transforming lives. But just where does your donation go?
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2022 (July 1, 2021–June 30, 2022)
-
Foundation News
The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for retinal degenerative diseases, will host an online continuing medical education (CME and COPE) course on inherited retinal disease gene therapies on Thursday, June 9, 2022, at 7:00 p.m. EDT.
-
Foundation News
The inaugural credit-based event will include education on inherited retinal diseases, physician resources, and current clinical trials.
-
What Does the Foundation's Statement of Financial Position Mean?
First and foremost, it means the Foundation Fighting Blindness (FFB) is in a strong position to continue to fund the most promising research on potential cures for retinal degenerative diseases and to help bring groundbreaking discoveries to clinical trials and the U.S. Food and Drug Administration (FDA) approval process.
-
Age-Related Macular Degeneration
DiseaseAge-related macular degeneration, or AMD, is the leading cause of blindness in people 55 and older in developed countries. The condition can lead to significant loss of central vision.
-
Foundation Commits $2 Million to Development of a Cross-Cutting Drug Treatment
NewsMitoChem Therapeutics has identified three compounds that appear to boost mitochondrial function and, thus, show potential for slowing vision loss caused by a variety of retinal degenerations.
-
Research News
The five-year grant will advance the emerging treatments toward clinical trials
-
Research News
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
